COMP <GO>

KPTI vs QNTM // NET PROFIT MARGIN

Karyopharm Therapeutics Inc. (NASDAQ) VS. Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ) • 15-METRIC TALLY: KPTI 1 — QNTM 1

■ METRIC PARITY

KPTI — Karyopharm Therapeutics Inc. ROARABLE E • RQD 31/100

LAST: $0.66 (-24.76%) • MKT CAP: $20.0M

DES <GO> FA <GO> 10-K RED <GO>

net-margins

-60.00%

QNTM — Quantum Biopharma Ltd. Class B Subordinate Voting Shares ROARABLE D • RQD 46/100

LAST: $2.38 (-2.46%) • MKT CAP: $20.7M

DES <GO> FA <GO> 10-K RED <GO>

net-margins

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KPTI VS. QNTM) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	KPTI	QNTM	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	—	—	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	—	—	TIE	/fcf-yield <GO>
Operating Margin	-60.00%	—	—	TIE	/operating-margins <GO>
Net Profit Margin ACTIVE	-60.00%	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	0.60%	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	—	—	TIE	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	51.4	38.1	+13.30	KPTI	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$20.0M	$20.7M	-$707.3K	QNTM	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	KPTI REV	QNTM REV	KPTI GROSS %	QNTM GROSS %	KPTI FCF	QNTM FCF
FY 2025	$146.1M	—	—	—	-$75.4M	—
FY 2024	$145.2M	—	—	—	-$127.6M	—
FY 2023	$146.0M	—	—	—	-$92.7M	—

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

KPTI // BETA —

QNTM // BETA —